Background. Treatment of acute human immunodeficiency virus (HIV) infection (AHI) decreases transmission and preserves immune function, but AHI diagnosis remains resource intensive. Risk-based scores predictive for AHI have been described for highrisk groups; however, symptom-based scores could be more generalizable across populations.
Early Test screening program. The Early Test is a free of charge, voluntary, community-based screening program in San Diego, California, in which participants are prospectively enrolled to receive point-of-care rapid HIV-1 Ab testing (INSTI HIV-1 Antibody Test, bioLytical Laboratories, Richmond, Canada), followed by routine (ie, independent of symptoms) reflex HIV NAT (Procleix Ultrio, Hologic, Bedford, Massachusetts) in all those who test Ab negative [11, 12, 22] ; blood samples for NAT testing are obtained at the time of HIV Ab testing. Those who tested positive for AHI (defined as a negative or indeterminate HIV antibody test in combination with a positive HIV NAT corresponding to Fiebig stages I-II 23) or early HIV infection (defined as HIV Ab positive/detuned enzyme immunoassay consistent with infection <70 days [24, 25] ) were enrolled to the San Diego Primary Infection Resource Consortium.
This analysis comprised individuals who tested positive for AHI from 2007 to 2017 and those who tested HIV NAT negative in 2017. A subset of participants with AHI has been described previously [17] . Participants with AHI were seen for follow-up (median, 6 days [interquartile range {IQR}, 4-8 days after testing), where a detailed symptom questionnaire was administered. Between January and July 2017, the symptom questionnaire was administered at the time of the HIV testing encounter (before test results were available) to all participants of the Early Test.
To examine possible recall bias due to the fact that most AHI cases completed the symptom questionnaire after their diagnosis, a sample of the most recent and consecutive early HIV infection cases with complete symptom questionnaires (n = 28) were included in a subanalysis that compared the number of symptoms reported between AHI, early HIV infection, and HIV-negative cases.
The symptom questionnaire assessed for 11 symptoms (headache, pharyngitis, skin rash, myalgia, fever, fatigue, night sweats, gastrointestinal symptoms [nausea, vomiting, or diarrhea], arthralgia, weight loss [≥2.5 kg], and lymphadenopathy) or other, which participants were asked to specify. The questionnaire assessed whether each symptom was present in the 14 days prior to testing.
Statistical Analysis
Statistical analysis was performed using SPSS Statistics, version 24 (IBM SPSS, Armonk, New York) and R version 3.1.1 programming language [26, 27] . Two-tailed significance level for this analysis was P < .05, and Bonferroni correction was used in instances of multiple comparisons.
Demographic and symptom data were compared between HIV-negative and AHI cases using Pearson χ 2 test, Fisher exact test, or Mann-Whitney U test as appropriate. Trends in symptom reporting over time among AHI cases were assessed using linear regression. The sample was randomized 2:1 into a derivation and validation dataset. In the derivation dataset, each symptom was entered into a univariate logistic regression model with AHI vs HIV-negative as the outcome. Odds ratios (ORs) including 95% confidence intervals (CIs) were calculated. Each symptom with P < .2 for AHI was entered in a multivariate logistic regression model. Model discrimination was assessed by the goodness-of-fit Hosmer-Lemeshow statistic [28] , and its predictive performance was assessed using receiver operating characteristic (ROC) analysis. Each significantly associated predictor in the multivariable model (P < .05) was assigned a point value that corresponded to its OR rounded to the nearest whole integer. Integer scores were subsequently summed to give the SDSS for each participant.
To test the validity of this new scoring system, we calculated the predictive potential of our new symptom score for AHI in the validation dataset. Score performance was assessed by ROC analysis and area under the curve (AUC) values with 95% CI. Cutoff values were determined using the Youden index. Different cutoffs were compared using the diagnostic odds ratio method.
For secondary analyses, the number of symptoms reported for the 14-day period prior to the testing event was compared between HIV-negative cases, early HIV infection cases, and AHI cases using Mann-Whitney U test. The proportion of participants reporting ≥2 symptoms was compared using Pearson χ 2 test.
The University of California, San Diego Human Research Protections Program approved the study protocol, consent, and all study-related procedures.
RESULTS

Cohort Characteristics
From June 2007 to February 2017, 115 participants were diagnosed with AHI with the Early Test and completed follow-up visits; 113 of 115 completed symptom data and comprised the AHI cases in the study sample.
From January to July of 2017, 885 NAT-negative testing encounters had complete symptom data and comprised the HIV-negative cases in the study sample.
Descriptive statistics for the study sample are shown in Table 1 . AHI cases and HIV-negative cases were similar by age, ethnicity, and most races. AHI cases were proportionally composed of more men, MSM, and Native Americans.
Symptoms
Each of the 11 symptoms was more frequently reported in AHI cases than HIV-negative cases ( Fifteen percent of AHI cases reported zero symptoms during the 14 days prior to testing, compared to 61.8% of HIV-negative cases (P < .001). Among patients with AHI, 56.6% reported zero ongoing symptoms, compared with 78.8% of HIV-negative patients (P < .001). There were significant, positive trends in number of symptoms reported by AHI cases over time, for both symptoms in the previous 14 days (P < .002) and symptoms ongoing at the time of testing (P < .001).
Among HIV-negative cases, men and women reported the same median number of symptoms in the past 14 days ; P = .064). There was also no difference in number of symptoms reported by race among AHI cases (data not shown).
Sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio for each symptom in isolation is shown in Table 3 . Specificity of symptoms ranged from 81% for headache to 98% for weight loss ≥2.5 kg, while sensitivity ranged from 19% for arthralgia to 60% for fever. Symptoms with positive likelihood ratios >10 were fever (14.01) and weight loss (13.99), whereas no symptoms had a negative likelihood ratio <0.10.
There was no difference in median number of symptoms reported between HIV-negative cases (median, 0 [IQR, 0-1]) and early HIV infection cases (median, 0 [IQR, 0-5.25]) (P = .34 with Bonferroni correction), whereas AHI cases reported more symptoms (median, 4 [IQR, [2] [3] [4] [5] [6] [7] ) than either early HIV infection cases (P = .008, corrected) or HIV-negative cases (P < .001, corrected). AHI cases had a significantly greater likelihood of reporting ≥2 symptoms (77.8% [95% CI, 69.1%-85.1%]) than either early HIV infection cases (35.7% [95% CI, 18.5%-55.9%]; P < .001) or HIV-negative cases (21.5% [95% CI, 18.8%-24.3%]; P < .001), whereas there was no significant difference between AHI and HIV-negative cases (P = .150).
San Diego Symptom Score Derivation
In the derivation set, each of the 11 symptoms (present in previous 14-day period) had a P value of < .2 in univariate logistic regression models for AHI vs HIV negative, and therefore all symptoms were entered into the multivariate model ( e Alaska Native, Native Hawaiian, unknown, or other (not specified). The symptom score was calculated for each case, with presence of fever, myalgia, and weight loss during the 14 days before the testing encounter conferring 11, 8, and 4 points respectively. A ROC curve in the derivation set yielded an AUC of 0.817 (95% CI, .759-.875; Figure 1 ).
San Diego Symptom Score Validation
The SDSS was calculated for each case in the validation set (n = 325). The score distribution among HIV-negative and AHI cases is shown in Table 5 . The SDSS produced a ROC curve with AUC 0.851 (95% CI, .780-.922) in the validation set (Figure 1) . The SDSS performed similarly when applied to the subset of MSM in the validation set (n = 248) with AUC 0.867 (95% CI, .789-.945). An optimal cutoff of 11 by Youden index was 72% sensitive and 96% specific, with a positive likelihood ratio of 20.33, negative likelihood ratio of 0.29, and diagnostic OR of 70.27 (95% CI, 28.14-175.93). Diagnostic parameters at other cutoffs are shown in Table 5 . The presence of all 3 symptoms (23 points total) was 100% specific for AHI; 8 AHI cases would have met this cutoff, yielding a sensitivity of 19%.
DISCUSSION
We assessed symptoms occurring during the 14 days before a voluntary community-based HIV testing encounter to construct and validate a simple multivariate symptom score for AHI, which may inform allocation of diagnostic and treatment resources in settings that do not routinely test for AHI.
Fever, fatigue, and myalgia were among the most commonly reported symptoms among AHI in our study, which is consistent with literature in the United States [18, 29, 30] . The relatively high specificity for each symptom is a function of our HIV-negative sample being relatively asymptomatic. Nearly 2 decades ago, Daar et al [18] compared the prevalence of symptoms between those with primary HIV infection and a comparator group that was recruited based on the presence of certain symptoms. That study was therefore not able to reliably assess frequency of symptoms in AHI negatives, making this the first study to systematically assess presence of symptoms in HIV-negative individuals presenting for voluntary routine AHI screening.
We also found that the number of symptoms reported among men vs women in HIV-negative cases and among older vs younger participants in HIV-negative and AHI cases did not differ. In a cohort study of individuals presenting for community-based screening in rural south Africa [31] , women and older presenters were more likely to cite feeling ill as a reason for testing, while men were more likely to present due to risky lifestyle.
This study raised important questions, one of them being whether this disparity in motivation truly reflects symptomatology, or rather cultural norms or taboos. Our findings appear to support the latter, while acknowledging that Early Test participants were not asked uniformly about motivations for testing.
To our knowledge, the SDSS is the first score to be derived from and validated in a cohort that included non-MSM. When applied to MSM only, the SDSS performed equally well, and appeared superior to published performances of risk based scores derived exclusively from MSM [12, [32] [33] [34] . For example, the SDET risk-based score, which was shown to be equally or more discriminatory than other risk-based scores [12] , yielded an AUC of 0.70 (95% CI, .63-.78). A recently published combined symptom and risk behavior score for MSM developed by Dijkstra et al [34] in the Netherlands had a validation AUC of 0.78 (95% CI, .74-.82). The performance of the Netherlands score may have been diminished by its methodology, where incident HIV infection was defined as seroconversions between follow-up visits, and routine identification of AHI using HIV NAT or p24 antigen testing was not performed. We believe that a symptom-based assessment is exempt from certain limitations inherent to risk-based scores. In a study by Hoenigl et al [35] that examined transmission clusters in southeast Austria using HIV-1 partial pol sequences, it was found that nearly half of clustering males who reported only heterosexual intercourse clustered closely with MSM.
The authors of that work propose possible explanations, one being that these individuals misreported their behaviors due to stigma. These individuals misreporting their risk may fall through the cracks in settings that use risk behavior-based scores. In contrast, symptoms may be less subject to stigma, and therefore individuals may be more comfortable disclosing symptoms than sexual behaviors. Another downside to riskbased scores is that, as previously discussed, reported risk factors are not uniform in a population, but differ based on race, sex, gender, and likely other factors [13, 36, 37] . For example, a recent cross-sectional study by Liu et al [38] assessing risk factors among Chinese migrant worker MSM in Beijing showed that the amount of time spent living in Beijing was independently associated with HIV infection, and migrant MSM were twice as likely to have HIV infection compared to local resident MSM. Overall, our findings using a symptom-based score in this study are encouraging. Future work to validate the SDSS outside the United States, particularly in resourcepoor settings, would lend further support to the notion that a symptom-based strategy for targeted NAT testing may be more generalizable between different sexes, genders, or behavioral risk patterns. Strengths of this study were (1) the prospective enrollment of participants; (2) systematic assessment of symptoms before the testing encounter in those who tested negative by Ab and NAT for HIV, allowing us to evaluate the specificity of symptoms; (3) the relatively large number of AHI cases compared to cohorts described in existing literature; and (4) the inclusion of non-MSM participants, comprising more than a quarter of our study sample.
There are also several important limitations to take into account. One limitation is that prior to 2017, symptoms for AHI cases were assessed after diagnosis, raising the concern that reported symptoms may be subjected to recall bias. However, we demonstrated that early HIV infection cases reported significantly fewer symptoms than AHI cases, despite the fact that their symptoms were also assessed after their diagnosis. This was reassuring, as the alternative finding (that AHI cases and early HIV infection cases reported a similar number of symptoms) would imply that reported symptoms may be primary driven by somatization or bias, rather than true symptoms. Other limitations include the single-center design of this study, and that our study sample was mainly white and with a significant proportion of Hispanics, which is representative of the Early Test cohort [22] but may differ from other settings in the United States [13] . In terms of self-identified gender, compared to previous published work with the Early Test cohort from a different time period [36, 37, 39] , our study sample had a slightly smaller proportion of transgender persons and women, and a greater proportion of MSM among male testers, reflecting time trends as well as ongoing preexposure prophylaxis studies specifically targeting women and transgender persons in San Diego. While frequency of symptoms did not differ between men and women who tested negative for HIV, we were not able to compare frequency of symptoms between sex or gender in those with AHI, due to the fact that MSM account for the vast majority of AHI diagnoses with the Early Test in San Diego.
In conclusion, the SDSS, a simple symptom score consisting of fever, myalgia, and weight loss of ≥2.5 kg in the 14 days prior to testing, was predictive of AHI in individuals who self-presented for community-based HIV testing. When selectively applied to MSM, the performance of the SDSS exceeded that reported for other risk behavior-based scores. Once validated in populations with differing demographics, the SDSS may inform allocation of resources in settings that do not routinely utilize NAT to detect AHI.
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